BRIEF-Tela Bio Announces Sale Of Distribution Rights For Wound Care Product To Mimedx-March 2024-www.financetom.com

BRIEF-Tela Bio Announces Sale Of Distribution Rights For Wound Care Product To Mimedx

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

BRIEF-Tela Bio Announces Sale Of Distribution Rights For Wound Care Product To Mimedx

Mar 20, 2024 4:32 AM

March 20 (Reuters) - TELA Bio Inc ( TELA ):

* TELA BIO ANNOUNCES SALE OF DISTRIBUTION RIGHTS FOR WOUND

CARE

PRODUCT TO MIMEDX

* TELA BIO INC ( TELA ) - AS CONSIDERATION FOR SALE, MIMEDX WILL MAKE

INITIAL $5.0 MILLION PAYMENT

* TELA BIO ( TELA )- MIMEDX WILL MAKE FUTURE PAYMENTS BETWEEN

MINIMUM OF

$3.0 MILLION AND $7.0 MILLION BASED ON NET SALES OF NIVIS OVER

NEXT TWO YEARS

Source text for Eikon:

Further company coverage:

Previous page： Top Midday Gainers Next page： BMO Reviews AutoCanada's Q4 -- Trims Target by $1, to $23

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Top Midday Gainers

Mar 8, 2024

02:21 PM EST, 03/08/2024 (MT Newswires) -- HCI Group ( HCI ) shares rose 13% after the company reported late Thursday Q4 results that topped analysts' estimates. More than 460,000 shares traded intraday compared with a daily average of about 104,000. Smith & Wesson Brands ( SWBI ) reported late Thursday stronger-than-expected Q3 results. Shares surged 28% as intraday trading...

BMO Reviews AutoCanada's Q4 -- Trims Target by $1, to $23

Mar 8, 2024

02:20 PM EST, 03/08/2024 (MT Newswires) -- AutoCanada's ( AOCIF ) Q4/23 headline EPS miss was due to unusual items in opex and higher-than-forecast underlying opex. The other parts of ACQ's Canadian business performed largely in line with BMO's expectations. The stock is trading at 6x BMO's revised 2025E EBITDA vs. historical range of 6-8x. Analyst Tamy Chen wonders if...

FDA approves Novo Nordisk's Wegovy for use in reducing heart attack risks

Mar 8, 2024

(Reuters) - The U.S. FDA has approved Novo Nordisk's Wegovy for use in lowering the risk of stroke and heart attack in overweight or obese adults who are not diabetic, the Danish drugmaker said on Friday. Novo's widely used diabetes drug Ozempic and weight-loss drug Wegovy, both chemically known as semaglutide, belong to a class of drugs called GLP-1 agonists....

Genesco Shares Decline Following Q4 Earnings Report

Mar 8, 2024

02:18 PM EST, 03/08/2024 (MT Newswires) -- Genesco ( GCO ) shares were down more than 11% in recent Friday trading following the company's fiscal Q4 earnings report. The company reported fiscal Q4 adjusted earnings of $2.59 per share, down from $3.06 a year ago. Two analysts polled by Capital IQ expected $2.62. Net sales for the quarter ended Feb....